Form 4: Aura Biosciences CEO Sells Shares for Tax Obligations
Insider Transaction Report
Aura Biosciences CEO Elisabet de los Pinos sold 9,049 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
Summary
- Elisabet de los Pinos, President and Chief Executive Officer of Aura Biosciences, Inc., reported a transaction on October 29, 2025.
- The transaction involved the disposition of 9,049 shares of Aura Biosciences common stock.
- The shares were sold at a price of $6.35 per share.
- The sale was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
- The sale was automatic and not at the discretion of the Reporting Person.
- Following the transaction, Elisabet de los Pinos directly owns 474,391 shares of common stock.
- Additionally, 127,763 shares are indirectly owned through the Elisabet de los Pinos Revocable Trust.
- The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Sentiment
Score: 5
Explanation: The sentiment is neutral. While it's an insider sale, it's explicitly for tax purposes related to RSU vesting and was automatic, which is a common and expected event, not indicative of a change in management's view of the company's prospects.
Positives
- The vesting of restricted stock units indicates ongoing compensation and retention of the CEO, aligning her interests with long-term company performance.
Negatives
- An insider sale, even for tax purposes, can sometimes be misinterpreted by the market as a lack of confidence, although the stated reason mitigates this concern.
Future Outlook
NA
Management Comments
- The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
- Such sales were automatic and not at the discretion of the Reporting Person.
Industry Context
This insider transaction is a routine event for executives receiving equity compensation, particularly restricted stock units, and does not reflect broader industry trends or competitive positioning.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Disclosure | The transaction was executed under a Rule 10b5-1(c) plan, which allows insiders to set up pre-scheduled trades to avoid accusations of trading on material non-public information. | 10/29/2025 | This demonstrates adherence to corporate governance best practices regarding insider trading, providing transparency and mitigating potential conflicts of interest. |
Related Party Transactions
- Elisabet de los Pinos indirectly holds 127,763 shares through the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which she is a trustee. This is a standard arrangement for personal asset management.
Stakeholder Impact
- Shareholders: The sale represents a very small percentage of the CEO's total holdings and the company's outstanding shares, thus having a negligible direct impact on share value or ownership structure.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 10/29/2025 | Date of earliest transaction reported for the sale of common stock. |
Keywords
Aura Biosciences, AURA, Form 4, Insider Transaction, Stock Sale, Elisabet de los Pinos, CEO, Restricted Stock Units, RSU, Tax Withholding, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.